AstraZeneca says its COVID-19 vaccine has strong immune response in older adults

AstraZeneca and the University of Oxford's COVID-19 vaccine candidate produces a strong immune response in older adults at high risk of severe illness if they contract the virus, according to phase 2 trial results published Nov. 18 in The Lancet. 

The phase 2 trial involved 560 healthy volunteers, and results show that the vaccine was able to prompt a response to COVID-19 within 14 days of the first dose. It produces a similar immune response among adults of all ages.

People over the age of 70 are at a high risk of developing severe illness if they contract COVID-19. The vaccine is now in phase 3 trials and is being tested to see if it can protect the elderly and people with underlying health conditions from COVID-19, The Hill reported. 

Phase 3 trial results should be known by Christmas, AstraZeneca and the University of Oxford said. 

Find the full study results here.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Articles We Think You'll Like